Commercial-stage biotechnology company Rocket Pharmaceuticals Inc (NASDAQ:RCKT) announced on Friday that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher, generating gross proceeds of USD180m.
The voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI, the company's gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening primary immunodeficiency.
Prior to the transaction, Rocket Pharmaceuticals reported cash, cash equivalents, and investments of USD144.4m as of 31 March 2026. Following the non-dilutive proceeds from the sale, pro forma cash, cash equivalents, and investments increased to approximately USD322.6m. The company expects this liquidity position to fund its operations into the second quarter of 2028.
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
FDA grants rare paediatric disease designation to RedHill's opaganib
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
Lupin's Ranluspec (ranibizumab) injection receives US FDA approval
Pharming secures FDA acceptance of Joenja filing for children with APDS
Medtronic seeks expanded US approvals for Hugo robotic surgery system
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan